The Cancer Biomarker Centre (CBC) at the CRUK Manchester Institute, University of Manchester, led by Prof Caroline Dive CBC aims to inform clinical trials of new anticancer drugs through translational research and biomarker science. The CBC hosts >70 staff within 9 specialist teams, including the Preclinical Pharmacology (PP) team, consisting of ~20 members. The PP Team works across cancer types with a focus on Small Cell Lung Cancer (SCLC) and has an international reputation in researching the biology and pharmacology of this aggressive cancer. The PP team pioneered preclinical models derived from patients’ Circulating Tumour Cells (CTCs), termed CDX, that faithfully mimic chemotherapy responses of donor patients and recapitulate the distribution of recently discovered molecular subtypes1,2. Our biobank of CDX models currently numbers > 60.
The lab are offering a unique opportunity for an experienced post-doctoral researcher looking to take the next step up in their career in translational research. You will have extensive hands-on experience of in vitro and in vivo preclinical cancer pharmacology with a track record of impactful publications. You will work closely with the PP Team Lead influencing the strategic direction and manage the day-to-day operational aspects of the Team’s research with line management responsibilities. PP team studies will predominantly focus on biomarker discovery and development and evaluation of novel therapy efficacies for SCLC but will also encompass preclinical pharmacology studies on other cancer types. The post holder (with appropriate training) will hold the CBC Home Office Project Licence and oversee all in vivo studies in accordance with Animals (Scientific Procedures) Act 1986 and specifically, with the Standard Conditions of the licence. The post holder will support the PP Team Lead in developing new collaboration opportunities with academics and with Pharma/Biotech companies to help achieve the CBC goal of translating preclinical experimental evidence to novel cancer precision medicines for patients.
1Hodgkinson et al., Nature Medicine (2014); 2Simpson et al., Nature Cancer (2020)
You will have a PhD in Biological sciences, ideally in cancer biology and/or cancer pharmacology, or a related discipline. A current or former Home Office Personal Licence holder is also essential. You will be a highly motivated, proactive, critical thinker with keen attention to detail. You will have extensive post-doctoral experience gained in academia or biotechnology plus extensive hands-on experience in working with in vitro/in vivo cancer pharmacology, with demonstrable expertise in designing and implementing in vivo studies to test novel therapeutic agents in accordance with Animals (Scientific Procedures) Act 1986. Experience in design and implementation of biomarker enhanced preclinical pharmacology studies and an appreciation of requirements to transition novel agents to personalised medicines for patients with cancer combined with a passion to improve patient outcomes.
The Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk), an Institute of The University of Manchester (www.manchester.ac.uk), is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org), the largest independent cancer research organisation in the world. On the 26th April 2017 The Paterson Building, which housed most of the Cancer Research UK (CRUK) Manchester Institute, suffered a fire resulting in significant damage. The rebuilding of our world-class research facilities is well underway, and we anticipate returning to our original site in Withington, Manchester (next to the Christie NHS Foundation Trust) in 2023. Initially, this position will be based at the internationally renowned life sciences campus at Alderley Park, Cheshire.
We are partnered with The Christie NHS Foundation Trust (adjacent to the CRUK MI Paterson Building) in South Manchester (www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.
To apply for this position please visit our website:
Please note this vacancy will close for applications at 11:59pm on the closing date specified.
Informal enquiries should be directed to:
(i) CBC Director Professor Caroline Dive Caroline.Dive@cruk.manchester.ac.uk or via linked in https://www.linkedin.com/in/professor-caroline-dive-cbe-79096314/
(ii) Preclinical Pharmacology Team lead Dr Kathryn Simpson Kathryn.Simpson@cruk.manchester.ac.uk or via LinkedIn https://www.linkedin.com/in/kathryn-simpson-6ab1b5a8/
Application deadline: 29 Jun 2022
Application deadline: 29 Jun 2022
The EACR is grateful for the continued support of its Industry Partners: